COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Multi-arm Phase 1b Study of Teclistamab with Other Anticancer Therapies in Participants with Multiple Myeloma

Protocol No
JANSSEN-64007957MMY1004
Principal Investigator
Anita D'Souza
Phase
I
Summary
The primary objectives of this study are to characterize the safety and tolerability of teclistamab combination regimens by assessing the incidence and severity of adverse events (AEs), laboratory values, and the frequency and type of dose-limiting toxicities (DLTs). A key secondary study objective is to evaluate antitumor activity of each treatment combination by assessing overall response as defined by International Myeloma Working Group (IMWG) 2016 response criteria, as well as duration of response and time to response.
Description
This trial is being done to assess the safety of teclistamab when administered with other anticancer therapies to identify the optimal dose(s) of this treatment combination regimen for adult participants with newly diagnosed or relapsed/refractory multiple myeloma.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL